In a recent article, “Trends in Oncology Dealmaking” published in BioPharma Dealmakers, analysts from Clarivate Analytics explored recent trends in oncology deals, and specifically immuno-oncology, which accounted for 32 of the 35 multibillion-dollar oncology licensing deals of the last five years. Join us on May 16 at 11AM EST as we discuss key findings from this article along with research from BioWorld and an insightful patent analysis based on data from the Derwent World Patents Index and the Derwent Patents Citation Index.
What topics will be discussed?